Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STK17A | Q9UEE5 | 15/20 | 0.54 |
| ▸ | STK17B | O94768 | 11/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1937398 | 0.95 | STK17A (0.56) | STK17ASTK17BNPSR1KDM4EL3MBTL1 | |
| SCHEMBL1934538 | 0.88 | STK17A (0.51) | STK17ASTK17BL3MBTL1KMT2A | |
| SCHEMBL25669146 | 0.85 | STK17A (0.48) | STK17ASTK17BNPSR1KDM4EL3MBTL1 | |
| SCHEMBL4188949 | 0.84 | KMT2A (0.47) | STK17ASTK17BNPSR1KDM4EL3MBTL1 | |
| SCHEMBL25584087 | 0.84 | KMT2A (0.44) | STK17ASTK17BNPSR1KDM4EL3MBTL1 | |
| SCHEMBL4194117 | 0.84 | TLR8 (0.44) | STK17ASTK17BNPSR1KDM4EL3MBTL1 | |
| SCHEMBL20154842 | 0.83 | STK17A (0.60) | STK17ASTK17B | |
| SCHEMBL1400319 | 0.81 | STK17A (0.56) | STK17ASTK17BKMT2ALMNASMN1; SMN2 | |
| SCHEMBL20652148 | 0.81 | STK17A (0.52) | STK17ASTK17BL3MBTL1 | |
| SCHEMBL1935303 | 0.80 | STK17B (0.47) | STK17ASTK17BL3MBTL1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10774092-B2 | ULK1 inhibitors and methods using same | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2020-09-15 | — | — | US | disclosed |
| US-10689397-B2 | ULK1 inhibitors and methods using same | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2020-06-23 | — | — | US | disclosed |
| US-20190284207-A1 | NOVEL ULK1 INHIBITORS AND METHODS USING SAME | SALK INSTITUTE FOR BIOLOGICAL STUDIES | 2019-09-19 | — | — | US | disclosed |
| US-20190248806-A1 | NOVEL ULK1 INHIBITORS AND METHODS USING SAME | SALK INSTITUTE FOR BIOLOGICAL STUDIES | 2019-08-15 | — | — | US | disclosed |
| US-20190152989-A1 | NOVEL ULK1 INHIBITORS AND METHODS USING SAME | SALK INSTITUTE FOR BIOLOGICAL STUDIES | 2019-05-23 | — | — | US | disclosed |
| US-10266549-B2 | ULK1 inhibitors and methods using same | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2019-04-23 | — | — | US | disclosed |
| US-20170342088-A1 | NOVEL ULK1 INHIBITORS AND METHODS USING SAME | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2017-11-30 | — | — | US | disclosed |
| EP-3185868-A1 | NOVEL ULK1 INHIBITORS AND METHODS USING SAME | Salk Institute for Biological Studies (US) | 2017-07-05 | — | — | EP | disclosed |
| WO-2016033100-A1 | NOVEL ULK1 INHIBITORS AND METHODS USING SAME | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2016-03-03 | — | — | WO | disclosed |
| US-20110230478-A1 | 4-Alkyl-substituted diaminopyrimidines | Bayer ScienceCrop AG (DE) | 2011-09-22 | — | — | US | disclosed |
| EP-2330904-A2 | 4-ALKYL-SUBSTITUTED DIAMINOPYRIMIDINES | Bayer CropScience AG (DE) | 2011-06-15 | — | — | EP | disclosed |
| WO-2010025863-A2 | 4-ALKYL-SUBSTITUTED DIAMINOPYRIMIDINES | BAYER CROPSCIENCE AG (DE) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10689397-B2 | ULK1 inhibitors and methods using same | ULK1, ULK2, ULK3 | STK17A 68/4885STK17B 129/4885NPSR1 4371/4885 |
| US-10266549-B2 | ULK1 inhibitors and methods using same | ULK1, ULK2, ULK3 | STK17A 68/4885STK17B 129/4885NPSR1 4371/4885 |
| US-20170342088-A1 | NOVEL ULK1 INHIBITORS AND METHODS USING SAME | ULK1, ULK2, ULK3 | STK17A 69/4885STK17B 116/4885NPSR1 4283/4885 |
| US-20110230478-A1 | 4-Alkyl-substituted diaminopyrimidines | DPM1, DPYD, POLR1C | STK17A 2888/4885STK17B 3187/4885NPSR1 4180/4885 |
| US-20190248806-A1 | NOVEL ULK1 INHIBITORS AND METHODS USING SAME | ULK1, ULK2, ULK3 | STK17A 69/4885STK17B 116/4885NPSR1 4283/4885 |
| US-20190152989-A1 | NOVEL ULK1 INHIBITORS AND METHODS USING SAME | ULK1, ULK2, ULK3 | STK17A 69/4885STK17B 116/4885NPSR1 4283/4885 |
| US-10774092-B2 | ULK1 inhibitors and methods using same | ULK1, ULK2, ULK3 | STK17A 68/4885STK17B 129/4885NPSR1 4371/4885 |
| US-20190284207-A1 | NOVEL ULK1 INHIBITORS AND METHODS USING SAME | ULK1, ULK2, ULK3 | STK17A 69/4885STK17B 116/4885NPSR1 4283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.